Cytek Biosciences (CTKB) Shares Outstanding (Weighted Average) (2020 - 2025)

Cytek Biosciences (CTKB) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $127.6 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Weighted Average) fell 2.7% year-over-year to $127.6 million; the trailing twelve-month figure through Jun 2025 stood at $127.6 million (down 2.7% YoY), and the FY2023 full-year result was $135.3 million, up 0.57% from the prior year.
• Shares Outstanding (Weighted Average) for Q2 2025 stood at $127.6 million, down from $131.1 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $136.2 million in Q3 2023 and bottomed at $31.6 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $132.5 million (2022), against an average of $115.6 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) surged 324.31%; it then declined 3.71% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $76.7 million in 2021, then soared by 75.28% to $134.5 million in 2022, then grew by 0.57% to $135.3 million in 2023, then dropped by 3.08% to $131.1 million in 2024, then retreated by 2.66% to $127.6 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $127.6 million (Q2 2025), $131.1 million (Q3 2024), and $131.2 million (Q2 2024), per Business Quant data.

Peer Comparison